Department of Internal Medicine, Toyooka Hospital Hidaka Medical Center, Toyooka, Hyogo, Japan.
Division of Clinical Nutrition, Faculty of Nutrition, Kobe Gakuin University, Kobe, Japan.
PLoS One. 2022 Mar 25;17(3):e0265637. doi: 10.1371/journal.pone.0265637. eCollection 2022.
Recent studies have suggested that chronic kidney disease is associated with cardiovascular disease, dementia, and frailty, all of which cause disability and early death. We investigated whether increased activity of urinary N-acetyl-β-glucosaminidase (NAG), a marker of kidney injury, is associated with risk of disability or all-cause mortality in a general population.
Follow-up data from the Hidaka Cohort Study, a population-based cohort study of members of a Japanese rural community, were obtained via questionnaires completed by participants or their relatives. Multivariable analyses were used to investigate relations between urinary NAG activity-urinary creatinine concentration ratio and risk of disability or all-cause mortality.
A total of 1182 participants were followed up for a median of 12.4 years. The endpoints were receipt of support under the public long-term care insurance program, and all-cause mortality. A total of 122 participants (10.3%) were reported to be receiving long-term care and 230 (19.5%) had died. After adjustment for cardiovascular risk factors along with physical activity, and using the quartile 1 results as a reference, the odds ratio (OR) for disability was 2.12 [95% confidence interval (95% confidence interval [CI]), 1.04-4.33; p = 0.038) and the hazard ratio (HR) for all-cause mortality was 1.65 (95% CI, 1.05-2.62; p = 0.031) in participants with urinary NAG/creatinine ratio in quartile 4. Similar results were obtained in participants without proteinuria: OR for disability, 2.46 (95% CI, 1.18-5.16; p = 0.017); and HR for all-cause mortality, 1.62 (95% CI, 1.00-2.63; p = 0.049).
Increased urinary NAG/creatinine ratio was associated with risk of disability or all-cause mortality in a general population.
最近的研究表明,慢性肾脏病与心血管疾病、痴呆和虚弱有关,所有这些都会导致残疾和早逝。我们研究了尿 N-乙酰-β-氨基葡萄糖苷酶(NAG)活性的增加,这种肾脏损伤的标志物,是否与一般人群的残疾或全因死亡率风险相关。
通过参与者或其亲属填写的问卷,获得了位于日本农村社区的比嘉队列研究的随访数据。多变量分析用于研究尿 NAG 活性与肌酐浓度比值与残疾或全因死亡率风险之间的关系。
共有 1182 名参与者接受了中位时间为 12.4 年的随访。终点是接受公共长期护理保险计划的支持,以及全因死亡率。共有 122 名参与者(10.3%)被报告接受长期护理,230 名参与者(19.5%)死亡。在调整心血管危险因素以及体力活动后,以四分位 1 的结果为参考,残疾的比值比(OR)为 2.12(95%置信区间[95%置信区间[CI],1.04-4.33;p=0.038),全因死亡率的危险比(HR)为 1.65(95%CI,1.05-2.62;p=0.031),在尿 NAG/肌酐比值位于四分位 4 的参与者中。在没有蛋白尿的参与者中也得到了类似的结果:残疾的 OR 为 2.46(95%CI,1.18-5.16;p=0.017);全因死亡率的 HR 为 1.62(95%CI,1.00-2.63;p=0.049)。
在一般人群中,尿 NAG/肌酐比值的增加与残疾或全因死亡率的风险相关。